Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy

Brazilian Journal of Infectious Diseases

Volumn 15, Issue 4, 2011, Pages 377-381

  De Oliveira Andrade, Luis Jesuino ^a   Atta, Ajax Mercês ^b   De Sousa Atta, Maria Luiza Brito ^b   Mangabeira, Célia Neder Kalil ^c   Paraná, Raymundo ^b  

^a DEPARTAMENTO DE CIÊNCIAS BIOLÓGICAS   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c UESC   (Brazil)

Author keywords

Autoimmunity; Hepatitis C; Interferon alpha; Ribavirin; Thyroid diseases

Indexed keywords

ALPHA INTERFERON; HEPATITIS C ANTIBODY; RIBAVIRIN; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROXINE; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; AGED; ANTIBODY TITER; ARTICLE; AUTOIMMUNE THYROIDITIS; BLOOD ANALYSIS; CLINICAL TRIAL; DISEASE ASSOCIATION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; THYROID DISEASE; THYROID FUNCTION TEST; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; TIME;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; THYROID DISEASES; THYROID FUNCTION TESTS; TIME FACTORS;

EID: 84856439885     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/S1413-8670(11)70208-2     Document Type: Article

References (23)

1. Tran H.A., Reeves G.E. The spectrum of autoimmune thyroid disease in the short to medium term following interferon-alpha therapy for chronic hepatitis C. Int J Endocrinol 2009, 2009:241786.
2. Tomer Y., Menconi F. Interferon induced thyroiditis. Best Pract Res Clin Endocrinol Metab 2009, 23:703-712.
3. Antonelli A., Ferri C., Fallahi P. Hepatitis C:thyroid dysfunction in patients with hepatitis C on IFN-alpha therapy. Nat Rev Gastroenterol Hepatol 2009, 6:633-635.
4. Tomer Y., Blackard J.T., Akeno N. Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am 2007, 36:1051-1066.
5. Snell N.J. Ribavirin - current status of a broad spectrum antiviral agent. Expert Opin Pharmacother 2001, 2:1317-1324.
6. Tam R.C., Lim C., Bard J., Pai B. Contact hypersensitivity responses following ribavirin treatment in vivo are influenced by type 1 cytokine polarization, regulation of IL-10 expression, and costimulatory signaling. J Immunol 1999, 163:3709-3717.
7. Koh L.K., Greenspan F.S., Yeo P.P. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 1997, 7:891-896.
8. Tran H.A., Reeves G.E. The influence of hepatitis C infection and interferon-alpha therapy on thyrotropin blocking and stimulating autoantibodies in Graves ophthalmopathy: a case report. Thyroid Res 2009, 2:12.
9. Zignego A.L., Craxì A. Extrahepatic manifestations of hepatitis C virus infection. Clin. Liver Dis 2008, 12:611-636.
10. Bartolomé J., Rodríguez-Iñigo E., Quadros P., et al. Detection of hepatitis C virus in thyroid tissue from patients with chronic HCV infection. J Med Virol 2008, 80:1588-1594.
11. Simmonds P., McOmish F., Yap P.L., et al. Sequence variability in the 5 non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. J Gen Virol 1993, 74:661-668.
12. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The Metavir Cooperative Study Group. Hepatology 1996, 24:289.
13. Bedossa P. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994, 20:15-20.
14. Tran H.A., Malcolm Reeves G.E., Gibson R., Attia J.R. Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis. J Gastroenterol Hepatol 2009, 24:1163-1168.
15. Prummel M.F., Laurberg P. Interferon-α and Autoimmune Thyroid Disease. Thyroid 2003, 13:547-551.
16. Bini E.J., Mehandru S. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. Arch Intern Med 2004, 164:2371-2376.
17. Mandac J.C., Chaudhry S., Sherman K.E., Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 2006, 43:661-672.
18. Duncea I., Pepene C.E. IFNalpha-induced recurrence of Graves disease ten years after thyroidectomy in chronic viral hepatitis C. Case report. J Gastrointestin Liver Dis 2008, 17:453-456.
19. Hsieh M.C., Yu M.L., Chuang W.L., et al. Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol 2000, 142:431-437.
20. Carella C., Mazziotti G., Amato G., Braverman L.E., Roti E. Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab 2004, 89:3656-3661.
21. Wong V., Fu A.X., George J., Cheung N.W. Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol (Oxf) 2002, 56:793-798.
22. Deutsch M., Dourakis S., Manesis E.K., et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997, 26:206-210.
23. Rodríguez-Torres M., Ríos-Bedoya C.F., Ortiz-Lasanta G., Marxuach-Cuétara A.M., Jiménez-Rivera J. Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis. Ann Hepatol 2008, 7:72-77.